We Think Oxford Nanopore Technologies (LON:ONT) Can Afford To Drive Business Growth
Mar 31
Have your own idea? Try our Stock Screener
U.K. (FTSE) Life Sciences Industry Analysis
UpdatedApr 14, 2026
DataAggregated Company Financials
Companies7
- 7D-8.9%
- 3M-25.7%
- 1Y-14.3%
- YTD-12.9%
Over the last 7 days, the Life Sciences industry has dropped 8.9%, driven by Oxford Nanopore Technologies declining 12%. Meanwhile, Diaceutics actually outperformed within the industry, gaining 7.4% in the last week. However, the industry is down 14% over the past year. As for the next few years, earnings are expected to grow by 54% per annum.
Industry Valuation and Performance
Has the U.K. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 14 Apr 2026 | UK£1.2b | UK£323.0m | -UK£156,192,254.00 | 9.5x | -8x | 3.9x |
| Thu, 12 Mar 2026 | UK£1.4b | UK£324.0m | -UK£161,423,254.00 | 11.1x | -8.7x | 4.3x |
| Sat, 07 Feb 2026 | UK£1.6b | UK£304.6m | -UK£159,441,254.00 | 7.9x | -10x | 5.3x |
| Mon, 05 Jan 2026 | UK£1.4b | UK£304.6m | -UK£159,441,254.00 | 8.2x | -9x | 4.7x |
| Wed, 03 Dec 2025 | UK£1.4b | UK£303.9m | -UK£162,910,254.00 | 7.1x | -8.8x | 4.7x |
| Fri, 31 Oct 2025 | UK£1.5b | UK£304.3m | -UK£163,156,254.00 | 8.4x | -9.4x | 5.1x |
| Sun, 28 Sep 2025 | UK£1.7b | UK£304.0m | -UK£163,375,352.00 | 9.9x | -10.2x | 5.5x |
| Tue, 26 Aug 2025 | UK£2.2b | UK£291.9m | -UK£160,968,352.00 | 6.4x | -13.9x | 7.6x |
| Thu, 24 Jul 2025 | UK£2.0b | UK£291.9m | -UK£160,968,352.00 | 6.2x | -12.6x | 6.9x |
| Sat, 21 Jun 2025 | UK£1.5b | UK£319.6m | -UK£191,020,739.20 | 6.5x | -8x | 4.8x |
| Mon, 19 May 2025 | UK£1.7b | UK£313.2m | -UK£193,016,833.70 | 11.5x | -8.6x | 5.3x |
| Wed, 16 Apr 2025 | UK£1.6b | UK£315.1m | -UK£185,785,984.75 | 6.4x | -8.8x | 5.2x |
| Fri, 14 Mar 2025 | UK£1.5b | UK£315.6m | -UK£186,172,571.15 | 6.3x | -7.9x | 4.7x |
| Sun, 09 Feb 2025 | UK£1.9b | UK£307.1m | -UK£195,645,066.48 | 6.8x | -9.8x | 6.2x |
| Tue, 07 Jan 2025 | UK£1.9b | UK£306.7m | -UK£195,372,758.16 | 7.6x | -9.9x | 6.3x |
| Thu, 05 Dec 2024 | UK£2.0b | UK£306.4m | -UK£194,826,079.44 | 8.3x | -10.5x | 6.7x |
| Sat, 02 Nov 2024 | UK£1.9b | UK£304.8m | -UK£192,652,400.50 | 11x | -9.9x | 6.3x |
| Mon, 30 Sep 2024 | UK£2.2b | UK£303.6m | -UK£191,718,111.40 | 11.1x | -11.4x | 7.2x |
| Wed, 28 Aug 2024 | UK£1.8b | UK£295.4m | -UK£188,112,477.00 | 12.4x | -9.8x | 6.3x |
| Fri, 26 Jul 2024 | UK£1.9b | UK£295.4m | -UK£189,849,942.69 | 12.5x | -10x | 6.4x |
| Sun, 23 Jun 2024 | UK£1.5b | UK£296.0m | -UK£190,309,224.21 | 11.5x | -7.7x | 5x |
| Tue, 21 May 2024 | UK£1.6b | UK£294.6m | -UK£187,451,926.31 | 8345.2x | -8.6x | 5.5x |
| Thu, 18 Apr 2024 | UK£1.5b | UK£317.7m | -UK£178,563,563.69 | 11.7x | -8.5x | 4.8x |
| Sat, 16 Mar 2024 | UK£1.9b | UK£295.6m | -UK£212,950,708.15 | 7176.9x | -8.8x | 6.3x |
| Mon, 12 Feb 2024 | UK£2.1b | UK£285.9m | -UK£189,301,187.46 | 7107.4x | -11x | 7.3x |
| Wed, 10 Jan 2024 | UK£3.0b | UK£450.0m | -UK£173,992,809.00 | 63.3x | -17x | 6.6x |
| Fri, 08 Dec 2023 | UK£3.0b | UK£452.9m | -UK£170,728,540.00 | 46.7x | -17.7x | 6.7x |
| Sun, 05 Nov 2023 | UK£3.2b | UK£458.1m | -UK£165,180,912.00 | 47.6x | -19.4x | 7x |
| Tue, 03 Oct 2023 | UK£3.0b | UK£449.0m | -UK£169,366,174.00 | 64.4x | -17.8x | 6.7x |
| Thu, 31 Aug 2023 | UK£3.1b | UK£476.1m | -UK£126,509,605.00 | 70.6x | -24.5x | 6.5x |
| Sat, 29 Jul 2023 | UK£3.4b | UK£476.2m | -UK£124,473,742.00 | 69.6x | -27.3x | 7.1x |
| Mon, 26 Jun 2023 | UK£2.9b | UK£476.6m | -UK£124,746,904.00 | 66.1x | -23.6x | 6.2x |
| Wed, 24 May 2023 | UK£3.2b | UK£477.9m | -UK£122,872,270.00 | 36.7x | -26.2x | 6.7x |
| Fri, 21 Apr 2023 | UK£3.0b | UK£462.7m | -UK£118,273,626.00 | 33.8x | -25.7x | 6.6x |
Price to Earnings Ratio
-25.7x
Current Industry PE
- Investors are pessimistic on the British Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 6.0x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have deteriorated over the last three years.
- Revenues have also declined 11% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | 1.71% | |
| Healthcare | -1.16% | |
| Life Sciences | -8.91% | |
| Clinical Research and Equipment | -8.91% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| HVO hVIVO | UK£0.087 | 26.1% +UK£12.2m | -47.0% | PE11.2x | |
| DXRX Diaceutics | UK£1.66 | 2.8% +UK£3.8m | 40.7% | PS4.1x | |
| FAB Fusion Antibodies | UK£0.14 | 7.7% +UK£1.3m | 109.0% | PS11x | |
| PYC Physiomics | UK£0.005 | 9.9% +UK£203.9k | 28.2% | PS2.2x |